Management of neuropathic pain after surgical and non-surgical trauma with lidocaine 5% patches: study of 40 consecutive cases

Hans, Guy; Joukes, E.; Verhulst, Johanna; Vercauteren, M.

doi:10.1185/03007990903282297

Cited by 29 publications

(40 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nearly 75% of treatment effects occurred during the first five treatment weeks but ongoing plaster administration provided sustained pain relief and amelioration of pain-related impairments during the entire observation period of up to 12 weeks. These patient-reported clinical practice data confirm the efficacy of the plaster shown for PHN and other neuropathic conditions in previous studies [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27] . The mean 5-point reduction in average pain intensity shown over the treatment period of 12 weeks compares well with the 2.5-point improvement observed in a large comparative study after 4 weeks in PHN and DPN patients with the same mean baseline pain intensity (6.9 points, NRS averaged over the three previous days) 13 .…”

Section: Discussionsupporting

confidence: 89%

“…Efficacy, tolerability, and safety of the plaster have been established for postherpetic neuralgia (PHN) in a number of randomised clinical studies [11][12][13][14][15] . Beneficial effects have also been demonstrated for other neuropathic pain states 13,[16][17][18][19][20] . Pain relief was observed for up to seven treatment years with daily plaster use [21][22][23][24] .…”

Section: Introductionmentioning

confidence: 90%

See 1 more Smart Citation

Patient perceptions associated with the 5% lidocaine medicated plaster in daily practice

Überall

Müller-Schwefe

2012

Current Medical Research and Opinion

View full text Add to dashboard Cite

In a patient population where 46% of individuals already suffered from chronic to markedly chronic pain, patients perceive the 5% lidocaine medicated plaster as an efficacious topical treatment of chronic neuropathic pain in daily clinical practice. Strongest pain relief as well as associated improvements in pain-related restrictions were observed within the first five treatment weeks; however, beneficial effects continued until end of observation.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 90%

Patient perceptions associated with the 5% lidocaine medicated plaster in daily practice

Überall

Müller-Schwefe

2012

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…7,8 In randomized studies, lidocaine patches were effective in patients with postherpetic neuralgia, 7 and open-label studies have suggested efficacy in other neuropathic pain conditions. 9 An analgesic effect of lidocaine patches in persistent postsurgical pain has been suggested, 10,11 but randomized controlled studies are lacking.…”

Section: Pain Medicinementioning

confidence: 99%

Lidocaine Patch (5%) in Treatment of Persistent Inguinal Postherniorrhaphy Pain

Bischoff

Petersen²,

Üçeyler

et al. 2013

Anesthesiology

View full text Add to dashboard Cite

Background: Evidence-based pharmacological treatment options for patients with persistent inguinal postherniorrhaphy pain are lacking. Methods: Twenty-one male patients, with severe, unilateral, persistent inguinal postherniorrhaphy pain, participated in a randomized, double-blind, placebo-controlled crossover trial, receiving lidocaine patch (5%) and placebo patch treatments in periods of 14 days separated by a 14-day wash-out period. Pain intensities (at rest, during movement, and pressure evoked [Numerical Rating Scale]) were assessed before treatment and on the last 3 days of each treatment period. Patients were a priori divided into two subgroups based on quantitative sensory testing (+/− thermal "hyposensitivity"). Skin biopsies for intraepidermal nerve fiber density assessment were taken at baseline, and quantitative sensory testing was performed before and after each treatment period. The primary outcome was change in pain intensity assessed as the difference in summed pain intensity differences between lidocaine and placebo patch treatments. Results: There was no difference in summed pain intensity differences between lidocaine and placebo patch treatments in all patients (mean difference 6.2% [95% CI = −6.6 to 18.9%]; P = 0.33) or in the two subgroups (+/− thermal "hyposensitivity"). The quantitative sensory testing (n = 21) demonstrated an increased pressure pain thresholds after lidocaine compared with placebo patch treatment. Baseline intraepidermal nerve fiber density (n = 21) was lower on the pain side compared with the nonpain side (−3.8 fibers per millimeter [95% CI = −6.1 to −1.4]; P = 0.003). One patient developed mild erythema in the groin during both treatments. Conclusions: Lidocaine patch treatment did not reduce combined resting and dynamic pain ratings compared with placebo in patients with severe, persistent inguinal postherniorrhaphy pain.

show abstract

“…Significant correspondence decreases in both pain intensity and LANSS score following treatment, as compared to no treatment, have been reported (36)(37)(38). In the present study, the LANSS Pain Scale was used for follow-up assessment of the treatment of NP; five patients in each group had a LANSS score <12 after one week of treatment and after one month of treatment; the reduction rate in the number of patients with NP was 33 percent.…”

Section: Discussionmentioning

confidence: 87%

The Efficacy of Gabapentin and Pregabalin in the Treatment of Neuropathic Pain due to Peripheral Nerve Injury

Kelle

Yavuz

Yaşar

et al. 2012

Journal of Musculoskeletal Pain

View full text Add to dashboard Cite

AObjective: The aim of this study was to compare the effectiveness of gabapentin and pregabalin in the treatment of neuropathic pain due to peripheral nerve injury. Methods: The study was designed to include military veterans with neuropathic pain due to combat-related peripheral nerve injury. The plan was to randomly assign the patients into two groups: Group 1 to receive gabapentin and Group 2 to receive pregabalin. The patients' level of pain at baseline, after one week, one month, and three months of treatment was to be assessed via a Visual Analog Scale [VAS] and the Leeds Assessment of Neuropathic Symptoms and Signs [LANSS] pain scale. The Sleep Interference Score was to be determined using an 11-point numerical rating scale at baseline and after three months of treatment. Results: Thirty patients were recruited into the study. Hence, Groups 1 and 2 were each composed of 15 patients. The mean reduction in VAS pain and LANSS scores from baseline to after the first week, first month, and third month of treatment was statistically significant in both the groups [P < 0.05]; however, there were not any significant differences in mean changes in VAS pain and LANSS scores between the two groups. The mean reduction in sleep interference score from baseline to after three months of treatment was significantly greater in Group 2 than in Group 1 [P = 0.001].Conclusions: There were no significant differences in the outcome of the treatment of neuropathic pain due to peripheral nerve injury between the two groups; however, pregabalin was superior to gabapentin in reducing the mean sleep interference score.

show abstract

Management of neuropathic pain after surgical and non-surgical trauma with lidocaine 5% patches: study of 40 consecutive cases

Abstract: Lidocaine 5% patches seem to be an effective treatment of post-surgical and post-traumatic pain. These results should be supported with randomised and placebo-controlled studies with larger sample sizes and longer follow-ups.

Cited by 29 publications

References 46 publications

Patient perceptions associated with the 5% lidocaine medicated plaster in daily practice

Patient perceptions associated with the 5% lidocaine medicated plaster in daily practice

Lidocaine Patch (5%) in Treatment of Persistent Inguinal Postherniorrhaphy Pain

The Efficacy of Gabapentin and Pregabalin in the Treatment of Neuropathic Pain due to Peripheral Nerve Injury

Contact Info

Product

Resources

About